Estrogen and progestogen use in postmenopausal women

July 2008 position statement of The North American Menopause Society

Wulf H. Utian, David F. Archer, Gloria A. Bachmann, John Christopher G. Gallagher, Francine Grodstein, Julia R. Heiman, Victor W. Henderson, Howard N. Hodis, Richard H. Karas, Rogerio A. Lobo, Jo Ann E Manson, Robert L. Reid, Peter J. Schmidt, Cynthia A. Stuenkel

Research output: Contribution to journalArticle

221 Citations (Scopus)

Abstract

Objective: To update for both clinicians and the lay public the evidence-based position statement published by The North American Menopause Society (NAMS) in March 2007 regarding its recommendations for menopausal hormone therapy (HT) for postmenopausal women, with consideration for the therapeutic benefit-risk ratio at various times through menopause and beyond. Design: An Advisory Panel of clinicians and researchers expert in the field of women's health was enlisted to review the March 2007 NAMS position statement, evaluate new evidence through an evidence-based analysis, and reach consensus on recommendations. The Panel's recommendations were reviewed and approved by the NAMS Board of Trustees as an official NAMS position statement. The document was provided to other interested organizations to seek their endorsement. Results: Current evidence supports a consensus regarding the role of HT in postmenopausal women, when potential therapeutic benefits and risks around the time of menopause are considered. This paper lists all these areas along with explanatory comments. Conclusions that vary from the 2007 position statement are highlighted. Addenda include a discussion of risk concepts, a new component not included in the 2007 paper, and a recommended list of areas for future HT research. A suggested reading list of key references is also provided. Conclusions: Recent data support the initiation of HT around the time of menopause to treat menopause-related symptoms; to treat or reduce the risk of certain disorders, such as osteoporosis or fractures in select postmenopausal women; or both. The benefit-risk ratio for menopausal HT is favorable close to menopause but decreases with aging and with time since menopause in previously untreated women.

Original languageEnglish
Pages (from-to)584-602
Number of pages19
JournalMenopause
Volume15
Issue number4
DOIs
StatePublished - Jul 2008
Externally publishedYes

Fingerprint

Progestins
Menopause
Estrogens
Hormones
Therapeutics
Odds Ratio
Trustees
Women's Health
Osteoporosis
Reading
Research Personnel
Research

All Science Journal Classification (ASJC) codes

  • Obstetrics and Gynecology

Cite this

Estrogen and progestogen use in postmenopausal women : July 2008 position statement of The North American Menopause Society. / Utian, Wulf H.; Archer, David F.; Bachmann, Gloria A.; Gallagher, John Christopher G.; Grodstein, Francine; Heiman, Julia R.; Henderson, Victor W.; Hodis, Howard N.; Karas, Richard H.; Lobo, Rogerio A.; Manson, Jo Ann E; Reid, Robert L.; Schmidt, Peter J.; Stuenkel, Cynthia A.

In: Menopause, Vol. 15, No. 4, 07.2008, p. 584-602.

Research output: Contribution to journalArticle

Utian, WH, Archer, DF, Bachmann, GA, Gallagher, JCG, Grodstein, F, Heiman, JR, Henderson, VW, Hodis, HN, Karas, RH, Lobo, RA, Manson, JAE, Reid, RL, Schmidt, PJ & Stuenkel, CA 2008, 'Estrogen and progestogen use in postmenopausal women: July 2008 position statement of The North American Menopause Society', Menopause, vol. 15, no. 4, pp. 584-602. https://doi.org/10.1097/gme.0b013e31817b076a
Utian, Wulf H. ; Archer, David F. ; Bachmann, Gloria A. ; Gallagher, John Christopher G. ; Grodstein, Francine ; Heiman, Julia R. ; Henderson, Victor W. ; Hodis, Howard N. ; Karas, Richard H. ; Lobo, Rogerio A. ; Manson, Jo Ann E ; Reid, Robert L. ; Schmidt, Peter J. ; Stuenkel, Cynthia A. / Estrogen and progestogen use in postmenopausal women : July 2008 position statement of The North American Menopause Society. In: Menopause. 2008 ; Vol. 15, No. 4. pp. 584-602.
@article{ece34c930d3949b2bbc6a84a0e600e97,
title = "Estrogen and progestogen use in postmenopausal women: July 2008 position statement of The North American Menopause Society",
abstract = "Objective: To update for both clinicians and the lay public the evidence-based position statement published by The North American Menopause Society (NAMS) in March 2007 regarding its recommendations for menopausal hormone therapy (HT) for postmenopausal women, with consideration for the therapeutic benefit-risk ratio at various times through menopause and beyond. Design: An Advisory Panel of clinicians and researchers expert in the field of women's health was enlisted to review the March 2007 NAMS position statement, evaluate new evidence through an evidence-based analysis, and reach consensus on recommendations. The Panel's recommendations were reviewed and approved by the NAMS Board of Trustees as an official NAMS position statement. The document was provided to other interested organizations to seek their endorsement. Results: Current evidence supports a consensus regarding the role of HT in postmenopausal women, when potential therapeutic benefits and risks around the time of menopause are considered. This paper lists all these areas along with explanatory comments. Conclusions that vary from the 2007 position statement are highlighted. Addenda include a discussion of risk concepts, a new component not included in the 2007 paper, and a recommended list of areas for future HT research. A suggested reading list of key references is also provided. Conclusions: Recent data support the initiation of HT around the time of menopause to treat menopause-related symptoms; to treat or reduce the risk of certain disorders, such as osteoporosis or fractures in select postmenopausal women; or both. The benefit-risk ratio for menopausal HT is favorable close to menopause but decreases with aging and with time since menopause in previously untreated women.",
author = "Utian, {Wulf H.} and Archer, {David F.} and Bachmann, {Gloria A.} and Gallagher, {John Christopher G.} and Francine Grodstein and Heiman, {Julia R.} and Henderson, {Victor W.} and Hodis, {Howard N.} and Karas, {Richard H.} and Lobo, {Rogerio A.} and Manson, {Jo Ann E} and Reid, {Robert L.} and Schmidt, {Peter J.} and Stuenkel, {Cynthia A.}",
year = "2008",
month = "7",
doi = "10.1097/gme.0b013e31817b076a",
language = "English",
volume = "15",
pages = "584--602",
journal = "Menopause",
issn = "1072-3714",
publisher = "Lippincott Williams and Wilkins",
number = "4",

}

TY - JOUR

T1 - Estrogen and progestogen use in postmenopausal women

T2 - July 2008 position statement of The North American Menopause Society

AU - Utian, Wulf H.

AU - Archer, David F.

AU - Bachmann, Gloria A.

AU - Gallagher, John Christopher G.

AU - Grodstein, Francine

AU - Heiman, Julia R.

AU - Henderson, Victor W.

AU - Hodis, Howard N.

AU - Karas, Richard H.

AU - Lobo, Rogerio A.

AU - Manson, Jo Ann E

AU - Reid, Robert L.

AU - Schmidt, Peter J.

AU - Stuenkel, Cynthia A.

PY - 2008/7

Y1 - 2008/7

N2 - Objective: To update for both clinicians and the lay public the evidence-based position statement published by The North American Menopause Society (NAMS) in March 2007 regarding its recommendations for menopausal hormone therapy (HT) for postmenopausal women, with consideration for the therapeutic benefit-risk ratio at various times through menopause and beyond. Design: An Advisory Panel of clinicians and researchers expert in the field of women's health was enlisted to review the March 2007 NAMS position statement, evaluate new evidence through an evidence-based analysis, and reach consensus on recommendations. The Panel's recommendations were reviewed and approved by the NAMS Board of Trustees as an official NAMS position statement. The document was provided to other interested organizations to seek their endorsement. Results: Current evidence supports a consensus regarding the role of HT in postmenopausal women, when potential therapeutic benefits and risks around the time of menopause are considered. This paper lists all these areas along with explanatory comments. Conclusions that vary from the 2007 position statement are highlighted. Addenda include a discussion of risk concepts, a new component not included in the 2007 paper, and a recommended list of areas for future HT research. A suggested reading list of key references is also provided. Conclusions: Recent data support the initiation of HT around the time of menopause to treat menopause-related symptoms; to treat or reduce the risk of certain disorders, such as osteoporosis or fractures in select postmenopausal women; or both. The benefit-risk ratio for menopausal HT is favorable close to menopause but decreases with aging and with time since menopause in previously untreated women.

AB - Objective: To update for both clinicians and the lay public the evidence-based position statement published by The North American Menopause Society (NAMS) in March 2007 regarding its recommendations for menopausal hormone therapy (HT) for postmenopausal women, with consideration for the therapeutic benefit-risk ratio at various times through menopause and beyond. Design: An Advisory Panel of clinicians and researchers expert in the field of women's health was enlisted to review the March 2007 NAMS position statement, evaluate new evidence through an evidence-based analysis, and reach consensus on recommendations. The Panel's recommendations were reviewed and approved by the NAMS Board of Trustees as an official NAMS position statement. The document was provided to other interested organizations to seek their endorsement. Results: Current evidence supports a consensus regarding the role of HT in postmenopausal women, when potential therapeutic benefits and risks around the time of menopause are considered. This paper lists all these areas along with explanatory comments. Conclusions that vary from the 2007 position statement are highlighted. Addenda include a discussion of risk concepts, a new component not included in the 2007 paper, and a recommended list of areas for future HT research. A suggested reading list of key references is also provided. Conclusions: Recent data support the initiation of HT around the time of menopause to treat menopause-related symptoms; to treat or reduce the risk of certain disorders, such as osteoporosis or fractures in select postmenopausal women; or both. The benefit-risk ratio for menopausal HT is favorable close to menopause but decreases with aging and with time since menopause in previously untreated women.

UR - http://www.scopus.com/inward/record.url?scp=51449124264&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=51449124264&partnerID=8YFLogxK

U2 - 10.1097/gme.0b013e31817b076a

DO - 10.1097/gme.0b013e31817b076a

M3 - Article

VL - 15

SP - 584

EP - 602

JO - Menopause

JF - Menopause

SN - 1072-3714

IS - 4

ER -